

Business Characteristics

Quick identification of even rare pathogens, contributing to rapid diagnoses in clinical settings



1. TFDA-certified mNGS platform capable of detecting tens of thousands of pathogen types in a single test

- With mNGS technology certified by the TFDA, it can detect more than 27,000 types of pathogens in a single test



2. Rapid diagnosis and precision medical support for overcoming unknown infectious diseases

- Capable of detecting unknown pathogens without setting targets, providing diagnostic reports within 24 to 48 hours



Matching Needs

Ideal profile of Tokyo companies

- Partners interested in the technology with regulatory experience in infectious disease testing
- Sales partners
- Investors interested in our technology


Objective

Expansion of sales channels in Japan, support for regulatory approval, and building partnerships with local medical and testing companies for clinical applications and market development

Using mNGS technology, it is possible to detect over 27,000 types of pathogens in a single test, contributing to a reduction in government healthcare costs and the improvement of patient survival rates.

Business Overview (Services/Products)

- APGSEQ® is based on metagenomic next-generation sequencing (mNGS) technology. It is capable of detecting over 27,000 types of pathogens, including bacteria, fungi, viruses, and parasites, within 24 to 48 hours, achieving a detection rate 62% higher than standard methods. The patented analysis system and genome database enable quicker and more accurate clinical decisions.



mNGS検出技術の使用

